Oncology News | pharmaphorum

News

MSD has another TIGIT programme setback

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi

News

NICE backs wider tumour profiling use in early breast cancer

Three tests that can be used to profile tumours in people with breast cancer and predict whether they will respond to chemotherapy have been cleared for wider use by the N

News

Citi analyst Andrew Baum to head Pfizer strategy team

Pfizer will draw on the expertise of Citi analyst Andrew Baum when it comes to portfolio management and capital deployment, naming him chief strategy and innovation office

News

Mariana Oncology's chief executive Simon Read

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Onc

News

Dr Elias Sayour, Chong Zhao and Arnav Barpujari discuss the mRNA cancer vaccine developed at the University of Florida

RNA glioblastoma vaccine shows promise in first human trial

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial.

News

Astellas expands Poseida alliance on solid tumour CAR-Ts

Astellas has clearly been impressed with a partnership signed last August with Poseida Therapeutics on the development of cell therapies for solid tumours, as it has just

MSD has another TIGIT programme setback

NICE backs wider tumour profiling use in early breast cancer

Citi analyst Andrew Baum to head Pfizer strategy team

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

RNA glioblastoma vaccine shows promise in first human trial

Astellas expands Poseida alliance on solid tumour CAR-Ts

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks